Harvoni (ledipasvir; sofosbuvir) Prior Authorization Request Form Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): ______AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Harvoni (ledipasvir; sofosbuvir) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Chronic hepatitis C virus				
Other Diagnosis ICD-10 Co	ode(s):	ΑΙ ΙΝΕΩΡΜΑΤΙΩΝ ΤΟ SUPPORT Α		
PRIOR AUTHORIZATION.				
Clinical Information:				
Is this a request for re-treatment with				
*If "yes," please submit patient chart i	notes with clinical rationale explaining v	why re-treatment is necessary.		
Does the patient have severe renal im	pairment (eGFR less than 30 mL/min/1.	73 m2) or end-stage renal disease		
(ESRD)? Yes No				
Is Harvoni prescribed by a hepatologis	t, gastroenterologist, or infectious disea	ase specialist? 🗆 Yes 🗆 No		
Document the patient's chronic hepat	itis C virus genotyne:*			
*Please provide supporting lab reports				
Is the patient a liver transplant recipie	nt? 🗆 Yes 🗆 No			
Does the patient have cirrhosis?				
Does the patient have decompensated liver disease (Child-Pugh class B or C)?□ Yes □ No				
Will Harvoni be used in combination with ribavirin? Yes No				
Select if the patient's treatment experience:				
□ Treatment-naive				
Previous treatment with peginterferon plus ribavirin				
Previous treatment with peginterferon plus ribavirin plus an HCV protease inhibitor				
Previous treatment with sofosbuvir-	based regimen			
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the				
physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.				



Harvoni (ledipasvir; sofosbuvir) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811